San Antonio Cardiovascular Proteomics Center, The University of Texas Health Science Center, San Antonio, TX 78245, USA.
Curr Drug Targets. 2013 Mar;14(3):276-86.
Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.
心肌梗死（MI）仍然是全球发病率和死亡率的主要原因。急性 MI 的治疗取得了快速进展，大大改善了患者的短期预后，这在很大程度上要归功于在缺血和随后的再灌注期间成功预防心肌细胞死亡和限制梗塞面积。基质金属蛋白酶（MMPs）在心肌梗死后心脏重构和不良结局的发展中发挥着关键作用。这篇综述强调了 MMPs 在左心室损伤和重构反应中的重要性，并讨论了它们作为治疗靶点的潜力。需要更多的临床前和临床研究来进一步研究和了解 MMPs 抑制剂的心脏保护作用。
